Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ralph Corey

Showing results (41-50 of 154) with videos related to

Pageof 16
Sort By:
The Lancet. Infectious Diseases|June 10, 2014
Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trialGregory J Moran, Edward Fang, G Ralph Corey, et al.
Journal of Medical Microbiology|September 16, 2003
Fatal outcome of bacteraemic patients caused by infection with staphylokinase-deficient Staphylococcus aureus strainsTao Jin, Maria Bokarewa, Lauren McIntyre, et al.
Circulation|September 15, 2005
Clinical predictors of major infections after cardiac surgeryVance G Fowler, Sean M O'Brien, Lawrence H Muhlbaier, et al.
Clinical Cardiology|August 4, 2005
The significance of elevated troponin T in patients with nondialysis-dependent renal insufficiency: a validation with coronary angiographyJohn F Heitner, Jeptha P Curtis, Salman A Haq, et al.
Antimicrobial Agents and Chemotherapy|August 20, 2014
Safety, tolerability, and efficacy of GSK1322322 in the treatment of acute bacterial skin and skin structure infectionsRalph Corey, Odin J Naderer, William D O'Riordan, et al.
Antimicrobial Agents and Chemotherapy|November 26, 2014
Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infectionsAndrew F Shorr, Thomas P Lodise, G Ralph Corey, et al.
Antimicrobial Agents and Chemotherapy|January 15, 2014
Telavancin for hospital-acquired pneumonia: clinical response and 28-day survivalG Ralph Corey, Marin H Kollef, Andrew F Shorr, et al.
The Journal of Antimicrobial Chemotherapy|March 15, 2012
Efficacy of telavancin in patients with specific types of complicated skin and skin structure infectionsMartin E Stryjewski, Steven L Barriere, William O'Riordan, et al.
Antimicrobial Agents and Chemotherapy|August 8, 2012
TD-1792 versus vancomycin for treatment of complicated skin and skin structure infectionsMartin E Stryjewski, Peter D Potgieter, Yu-Ping Li, et al.
Antimicrobial Agents and Chemotherapy|December 18, 2019
<i>In Vitro</i> Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017Ian Morrissey, Melanie Olesky, Stephen Hawser, et al.
Pageof 16

Showing results (41-50 of 154) with videos related to

Sort By:
Pageof 16
The Lancet. Infectious Diseases|June 10, 2014
Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trialGregory J Moran, Edward Fang, G Ralph Corey, et al.
Journal of Medical Microbiology|September 16, 2003
Fatal outcome of bacteraemic patients caused by infection with staphylokinase-deficient Staphylococcus aureus strainsTao Jin, Maria Bokarewa, Lauren McIntyre, et al.
Circulation|September 15, 2005
Clinical predictors of major infections after cardiac surgeryVance G Fowler, Sean M O'Brien, Lawrence H Muhlbaier, et al.
Clinical Cardiology|August 4, 2005
The significance of elevated troponin T in patients with nondialysis-dependent renal insufficiency: a validation with coronary angiographyJohn F Heitner, Jeptha P Curtis, Salman A Haq, et al.
Antimicrobial Agents and Chemotherapy|August 20, 2014
Safety, tolerability, and efficacy of GSK1322322 in the treatment of acute bacterial skin and skin structure infectionsRalph Corey, Odin J Naderer, William D O'Riordan, et al.
Antimicrobial Agents and Chemotherapy|November 26, 2014
Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infectionsAndrew F Shorr, Thomas P Lodise, G Ralph Corey, et al.
Antimicrobial Agents and Chemotherapy|January 15, 2014
Telavancin for hospital-acquired pneumonia: clinical response and 28-day survivalG Ralph Corey, Marin H Kollef, Andrew F Shorr, et al.
The Journal of Antimicrobial Chemotherapy|March 15, 2012
Efficacy of telavancin in patients with specific types of complicated skin and skin structure infectionsMartin E Stryjewski, Steven L Barriere, William O'Riordan, et al.
Antimicrobial Agents and Chemotherapy|August 8, 2012
TD-1792 versus vancomycin for treatment of complicated skin and skin structure infectionsMartin E Stryjewski, Peter D Potgieter, Yu-Ping Li, et al.
Antimicrobial Agents and Chemotherapy|December 18, 2019
<i>In Vitro</i> Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017Ian Morrissey, Melanie Olesky, Stephen Hawser, et al.
Pageof 16